NI201100160A - Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 - Google Patents
Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3Info
- Publication number
- NI201100160A NI201100160A NI201100160A NI201100160A NI201100160A NI 201100160 A NI201100160 A NI 201100160A NI 201100160 A NI201100160 A NI 201100160A NI 201100160 A NI201100160 A NI 201100160A NI 201100160 A NI201100160 A NI 201100160A
- Authority
- NI
- Nicaragua
- Prior art keywords
- cyclopropylamide
- histamine
- receptor
- derivatives
- targeted against
- Prior art date
Links
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical class NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004384 Histamine H3 receptors Human genes 0.000 title abstract 2
- 108090000981 Histamine H3 receptors Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15406709P | 2009-02-20 | 2009-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100160A true NI201100160A (es) | 2012-03-15 |
Family
ID=42631518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100160A NI201100160A (es) | 2009-02-20 | 2011-08-19 | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 |
Country Status (39)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2655604C (en) * | 2006-06-23 | 2016-08-09 | Abbott Laboratories | Cyclopropyl amine derivatives |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| BRPI0815591B8 (pt) * | 2007-08-22 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e, uso de um composto. |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| US9186353B2 (en) | 2009-04-27 | 2015-11-17 | Abbvie Inc. | Treatment of osteoarthritis pain |
| MX2012009537A (es) * | 2010-02-18 | 2012-08-31 | Astrazeneca Ab | Formas solidas que comprenden un derivado de ciclopropilamida. |
| AU2011218491C1 (en) * | 2010-02-18 | 2015-05-14 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| US8853390B2 (en) | 2010-09-16 | 2014-10-07 | Abbvie Inc. | Processes for preparing 1,2-substituted cyclopropyl derivatives |
| US9840481B2 (en) | 2016-03-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Allosteric modulators of nicotinic acetylcholine receptors |
| EP4215534B1 (en) | 2020-09-18 | 2026-06-24 | Carna Biosciences, Inc. | Amine derivative |
| CN114790186B (zh) * | 2021-01-25 | 2026-04-28 | 武汉人福创新药物研发中心有限公司 | 作为ep4拮抗剂的稠环化合物及其制备方法和用途 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL297170A (enExample) * | 1963-04-04 | 1900-01-01 | ||
| NL128365C (enExample) | 1963-11-05 | |||
| US3449427A (en) * | 1965-06-03 | 1969-06-10 | Smithkline Corp | Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes |
| US3697506A (en) | 1970-08-07 | 1972-10-10 | Pfizer | Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor |
| US3686335A (en) * | 1970-12-21 | 1972-08-22 | Smith Kline French Lab | 5-vinyl-5h-di benzo(a,d)cycloheptenes |
| US4432987A (en) | 1982-04-23 | 1984-02-21 | Pfizer Inc. | Crystalline benzenesulfonate salts of sultamicillin |
| US4547505A (en) * | 1983-03-25 | 1985-10-15 | Degussa Aktiengesellschaft | N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production |
| CS244821B2 (en) | 1983-06-16 | 1986-08-14 | Boehringer Ingelheim Ltd | Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas |
| DE3418167A1 (de) | 1984-05-16 | 1985-11-21 | Bayer Ag, 5090 Leverkusen | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden |
| DE3600288A1 (de) | 1986-01-08 | 1987-07-16 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten |
| DE3618004A1 (de) | 1986-05-28 | 1987-12-03 | Bayer Ag | Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| CA2033390A1 (en) * | 1989-12-29 | 1991-06-30 | Susumu Nakagawa | 2-(2-cyclopropylpyrrolidin-4-ylthio) carbapenem derivatives |
| EP0603240B1 (en) | 1991-08-22 | 1998-12-02 | Monsanto Company | Safening herbicidal pyrazolylsulfonylureas |
| DE4131139A1 (de) | 1991-09-19 | 1993-03-25 | Bayer Ag | Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure |
| ATE202109T1 (de) | 1993-03-12 | 2001-06-15 | Upjohn Co | Kristallines ceftiofur (freie säure) |
| EP0793653A1 (en) | 1994-11-23 | 1997-09-10 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US5604253A (en) | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
| US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
| EP0968200A1 (en) | 1997-02-24 | 2000-01-05 | ZymoGenetics, Inc. | Calcitonin mimetics |
| US6160134A (en) | 1997-12-24 | 2000-12-12 | Bristol-Myers Squibb Co. | Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines |
| YU47600A (sh) | 1998-01-27 | 2002-09-19 | Aventis Pharmaceuticals Products Inc. | SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| WO2000000492A1 (en) | 1998-06-26 | 2000-01-06 | Chugai Seiyaku Kabushiki Kaisha | FINE POWDER OF L-α-AMINOADIPIC ACID DERIVATIVE, ORAL SOLID PREPARATIONS CONTAINING THE SAME, AND METHOD FOR TREATMENT OF BULK POWDERS |
| AU771199B2 (en) | 1999-01-08 | 2004-03-18 | Neurogen Corporation | 1-phenyl-4-(1-(2-aryl)cyclopropyl) methylpiperazines: dopamine receptor ligands |
| US6284761B1 (en) * | 1999-01-08 | 2001-09-04 | Neurogen Corporation | 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands |
| AU5426500A (en) | 1999-06-16 | 2001-01-02 | Takeda Chemical Industries Ltd. | Benzazepine derivatives, process for the preparation of the same and uses thereof |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US6521619B2 (en) * | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| WO2002002522A1 (en) | 2000-06-29 | 2002-01-10 | Abbott Laboratories | Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| IL153884A0 (en) | 2000-07-20 | 2003-07-31 | Neurogen Corp | Capsaicin receptor ligands |
| JPWO2002051781A1 (ja) | 2000-12-25 | 2004-04-22 | 味の素株式会社 | 光学活性ハロヒドリン化合物の製造方法 |
| MXPA03007621A (es) | 2001-02-23 | 2003-12-04 | Merck & Co Inc | Antagonistas nr2b de n-metil-d-aspartato no arilheterociclicos n-sustituidos. |
| WO2003004480A2 (en) | 2001-07-02 | 2003-01-16 | Novo Nordisk A/S | Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| EP1422228A1 (en) | 2001-08-08 | 2004-05-26 | Takeda Chemical Industries, Ltd. | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE |
| WO2003026572A2 (en) | 2001-09-26 | 2003-04-03 | Merck & Co., Inc. | Crystalline forms of ertapenem sodium |
| AU2002363236A1 (en) | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| US6861432B2 (en) * | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
| JP2005526800A (ja) | 2002-03-22 | 2005-09-08 | エルジー・ライフ・サイエンシーズ・リミテッド | （２Ｓ）−Ｎ−５−［アミノ（イミノ）メチル］−２−チエニルメチル−１−（２Ｒ）−２−［（カルボキシルメチル）アミノ］−３，３−ジフェニルプロパノイル−２−ピロリジンカルボキサミド・ｎＨ２Ｏの新しい結晶形 |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| US20040077618A1 (en) | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| US20040209858A1 (en) * | 2002-10-22 | 2004-10-21 | Bennani Youssef L. | Cycloalkylamides and their therapeutic applications |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| ES2298627T3 (es) | 2002-12-13 | 2008-05-16 | Smithkline Beecham Corporation | Compuestos de ciclopropilo como antagonistas de ccr5. |
| HRP20080541T3 (en) | 2003-04-23 | 2008-12-31 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| EP1617840A4 (en) | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| ZA200605248B (en) | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | Cyclopropane compounds and pharmaceutical use thereof |
| BRPI0418939A (pt) | 2004-07-06 | 2008-04-08 | Xenon Pharmaceuticals Inc | derivados de nicotinamida e sua utilização como agentes terapêuticos |
| AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| BRPI0515851A (pt) | 2004-09-29 | 2008-08-12 | Mitsubishi Pharma Corp | composto de pirimidona |
| US20080045506A1 (en) | 2004-10-15 | 2008-02-21 | Glaxo Group Limited | Pyrrolidine Derivatives as Histamine Receptors Ligands |
| BRPI0517423A (pt) | 2004-12-27 | 2008-10-07 | Astrazeneca Ab | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto |
| CA2595882A1 (en) | 2005-01-26 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation |
| JP2008530162A (ja) | 2005-02-15 | 2008-08-07 | グラクソ グループ リミテッド | グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用 |
| MX2007010076A (es) | 2005-02-17 | 2007-10-16 | Astellas Pharma Inc | Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo. |
| WO2006100591A1 (en) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| CA2602227A1 (en) | 2005-03-28 | 2006-10-05 | Michael Dalton Ennis | 4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| EP1896483A2 (en) | 2005-03-28 | 2008-03-12 | Pharmacia & Upjohn Company LLC | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| CA2602538A1 (en) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| CN101263125A (zh) | 2005-07-15 | 2008-09-10 | 先灵公司 | 用于癌症治疗的喹唑啉衍生物 |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| WO2007016496A2 (en) | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| KR101336106B1 (ko) * | 2005-09-16 | 2013-12-05 | 얀센 파마슈티카 엔.브이. | 히스타민 ｈ3 수용체의 조절제로서 사이클로프로필 아민 |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| DK1951699T3 (da) | 2005-10-31 | 2013-01-14 | Janssen Pharmaceutica Nv | Fremgangsmåder til fremstilling af cyclopropylamidderivater |
| WO2007075895A2 (en) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2007076140A2 (en) | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| BRPI0707916A2 (pt) * | 2006-01-13 | 2011-05-17 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos |
| CN101384581B (zh) | 2006-02-17 | 2013-09-18 | 弗·哈夫曼-拉罗切有限公司 | 作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物 |
| US20100006010A1 (en) | 2006-03-01 | 2010-01-14 | Ihor Hinczak | Matrix for masonry elements and method of manufacture thereof |
| JP2009132621A (ja) | 2006-03-13 | 2009-06-18 | Ajinomoto Co Inc | シクロプロピルアミド化合物の製造方法 |
| AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| WO2007138928A1 (ja) | 2006-05-26 | 2007-12-06 | Kaneka Corporation | 光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法 |
| CA2655604C (en) * | 2006-06-23 | 2016-08-09 | Abbott Laboratories | Cyclopropyl amine derivatives |
| US9108948B2 (en) * | 2006-06-23 | 2015-08-18 | Abbvie Inc. | Cyclopropyl amine derivatives |
| AU2007271187A1 (en) | 2006-07-03 | 2008-01-10 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Fused bicyclic compounds interacting with the histamine H4 receptor |
| US20090247499A1 (en) | 2006-08-21 | 2009-10-01 | Fletcher Joan M | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| TW200828371A (en) | 2006-09-21 | 2008-07-01 | Matsushita Electric Industrial Co Ltd | Chip-type filter |
| DE102006056526A1 (de) | 2006-11-30 | 2008-06-05 | Archimica Gmbh | Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| WO2008147864A2 (en) * | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| JP2010529157A (ja) * | 2007-06-11 | 2010-08-26 | エフ．ホフマン−ラ ロシュ アーゲー | シクロヘキシル誘導体 |
| BRPI0815591B8 (pt) * | 2007-08-22 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e, uso de um composto. |
| KR101178674B1 (ko) | 2007-10-04 | 2012-08-30 | 에프. 호프만-라 로슈 아게 | 사이클로프로필 아릴 아마이드 유도체 및 이의 용도 |
| AR070107A1 (es) | 2008-01-15 | 2010-03-17 | Lilly Co Eli | R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia |
| DE102008049371A1 (de) | 2008-03-06 | 2009-09-10 | Mühlbauer Ag | Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür |
| CA2721303C (en) | 2008-05-08 | 2016-06-28 | Evotec Ag | Azetidines and cyclobutanes as histamine h3 receptor antagonists |
| JP2012503595A (ja) | 2008-07-28 | 2012-02-09 | シダンスク ユニバーシティ | 代謝病の治療用の化合物 |
| CN101462980B (zh) | 2009-01-05 | 2013-01-09 | 扬州天辰精细化工有限公司 | 2，6—二氟苯甲酰胺的工业化生产方法 |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| AU2011218491C1 (en) * | 2010-02-18 | 2015-05-14 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| MX2012009537A (es) * | 2010-02-18 | 2012-08-31 | Astrazeneca Ab | Formas solidas que comprenden un derivado de ciclopropilamida. |
-
2010
- 2010-02-12 TW TW099104778A patent/TW201039825A/zh unknown
- 2010-02-17 SA SA110310136A patent/SA110310136B1/ar unknown
- 2010-02-19 PT PT107440281T patent/PT2398780E/pt unknown
- 2010-02-19 JP JP2011551039A patent/JP5666480B2/ja not_active Expired - Fee Related
- 2010-02-19 DK DK10744028.1T patent/DK2398780T3/da active
- 2010-02-19 WO PCT/SE2010/050191 patent/WO2010096011A1/en not_active Ceased
- 2010-02-19 MX MX2011008280A patent/MX2011008280A/es active IP Right Grant
- 2010-02-19 UA UAA201109215A patent/UA108841C2/ru unknown
- 2010-02-19 HR HRP20130579AT patent/HRP20130579T1/hr unknown
- 2010-02-19 PE PE2015001189A patent/PE20151281A1/es not_active Application Discontinuation
- 2010-02-19 US US12/708,550 patent/US8993577B2/en not_active Expired - Fee Related
- 2010-02-19 CA CA2752796A patent/CA2752796A1/en not_active Abandoned
- 2010-02-19 AU AU2010216454A patent/AU2010216454B2/en not_active Ceased
- 2010-02-19 EP EP10744028.1A patent/EP2398780B1/en active Active
- 2010-02-19 RS RS20130280A patent/RS52851B/sr unknown
- 2010-02-19 CN CN201080017452.0A patent/CN102405213B/zh not_active Expired - Fee Related
- 2010-02-19 PL PL10744028T patent/PL2398780T3/pl unknown
- 2010-02-19 ME MEP-2013-74A patent/ME01619B/me unknown
- 2010-02-19 PE PE2011001527A patent/PE20120063A1/es not_active Application Discontinuation
- 2010-02-19 SG SG2011053477A patent/SG173449A1/en unknown
- 2010-02-19 ES ES10744028T patent/ES2416464T3/es active Active
- 2010-02-19 NZ NZ595248A patent/NZ595248A/en not_active IP Right Cessation
- 2010-02-19 UY UY0001032460A patent/UY32460A/es not_active Application Discontinuation
- 2010-02-19 BR BRPI1007817A patent/BRPI1007817A2/pt not_active IP Right Cessation
- 2010-02-19 SI SI201030257T patent/SI2398780T1/sl unknown
- 2010-02-19 EA EA201190140A patent/EA020093B1/ru not_active IP Right Cessation
- 2010-02-19 AR ARP100100499A patent/AR075531A1/es unknown
- 2010-02-19 KR KR1020117019311A patent/KR20110126628A/ko not_active Withdrawn
- 2010-02-19 EA EA201490268A patent/EA201490268A1/ru unknown
- 2010-02-19 CN CN201410557796.0A patent/CN104398516A/zh active Pending
-
2011
- 2011-07-25 IL IL214277A patent/IL214277A/en not_active IP Right Cessation
- 2011-07-29 CO CO11095921A patent/CO6400219A2/es active IP Right Grant
- 2011-08-19 DO DO2011000270A patent/DOP2011000270A/es unknown
- 2011-08-19 EC EC2011011280A patent/ECSP11011280A/es unknown
- 2011-08-19 HN HN2011002261A patent/HN2011002261A/es unknown
- 2011-08-19 SV SV2011004008A patent/SV2011004008A/es unknown
- 2011-08-19 NI NI201100160A patent/NI201100160A/es unknown
- 2011-08-19 CR CR20110447A patent/CR20110447A/es unknown
- 2011-08-19 CU CU20110161A patent/CU20110161A7/es unknown
- 2011-09-19 ZA ZA2011/06821A patent/ZA201106821B/en unknown
-
2013
- 2013-07-04 SM SM201300077T patent/SMT201300077B/xx unknown
-
2014
- 2014-02-06 CU CU2014000013A patent/CU20140013A7/es unknown
- 2014-12-09 JP JP2014248499A patent/JP2015071634A/ja active Pending
-
2015
- 2015-02-24 US US14/630,514 patent/US20150164888A1/en not_active Abandoned
- 2015-02-24 US US14/630,530 patent/US20150164889A1/en not_active Abandoned
- 2015-09-11 HK HK15108903.2A patent/HK1208348A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20140013A7 (es) | Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3 | |
| NI201000031A (es) | Derivados de ciclopropilamida. | |
| CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
| UY32640A (es) | Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona | |
| GT201300258A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
| UY32111A (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
| UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| ECSP12011585A (es) | Compuestos y composiciones para eltratamiento de enfermedades parasitarias | |
| CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
| ECSP099754A (es) | Derivados de la espirociclopropil piperidina | |
| PA8846201A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
| HN2011001247A (es) | Inhibidores de cinana akt y p70 s6 | |
| CO6382130A2 (es) | Nuevos compuestos de imidazolidina como moduladores del receptor de androdenos | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| CO6260091A2 (es) | Derivados de iminopiridina y su uso | |
| UY31335A1 (es) | Tratamiento de sintomas vasomotores | |
| UY32258A (es) | Derivados de la espirociclobutilpiperidina | |
| ATE481395T1 (de) | Cyclohexylderivate | |
| CR11549A (es) | Composición y procedimiento para el tratamiento de la cercosporiosis del banano | |
| UY31303A1 (es) | Derivados de ciclopropil amida 978 | |
| CY1114176T1 (el) | Παραγωγα κυκλοπροπυλαμιδιου που στοχευουν τον υποδοχεα η3 της ισταμινης | |
| CY1116993T1 (el) | Μεθοδος μειωσης της ενδοφθαλμιας πιεσης σε ανθρωπους | |
| CL2010001230A1 (es) | Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis. | |
| ECSP10010028A (es) | Tratamiento de síntomas vasomotores |